Stock Ratings / Health Care / ETRA / financials

ENTX (40) VALN (48) SRZN (38) RGNX (27) ⌘ Pro Terminal →

Electra Therapeutics Inc. (ETRA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is Electra Therapeutics Inc. (ETRA)?

In Trailing 12 Months, ETRA converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $15.2M in free cash flow (0.4% FCF margin).

$8.10 -6.25% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.99

Electra Therapeutics Inc. (ETRA) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $542.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ETRA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ETRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Electra Therapeutics Inc. (NASDAQ: ETRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $8.10 (-6.25% 1D, market cap $542.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ETRA compare to ENTX and VALN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ETRA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ENTX (Entera Bio Ltd.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -33.6%, cap $542.6M) and VALN (Valneva SE) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $541.8M). Among the 5-stock peer group, ETRA leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ETRA?

▼

For Electra Therapeutics Inc. (ETRA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #458 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $7.99 (-1.31%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ETRA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY ETRA SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (28% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($15.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$9.32-7.6% Next Q

Q2 (-2Q)

Grade D$8.61-2.8% Next Q

Q3 (-1Q)

Grade D$8.37-3.2% Next Q

Current

Grade D-$8.10-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ETRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ETRA currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.92) and Max Pain ($8.51) forces dealer call-delta covering toward $16.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ETRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ETRA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How ETRA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$15.2M (0.4% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ETRA)

✓Walkthrough of ETRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ETRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.87%🛡️ HOLDING TREND SUPPORT

2026-11-02O $8.00H $8.38L $7.05C $8.10VOL 385.5K

SUP: $8.06SMA50: $9.92SMA200: $9.94

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ETRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ETRA Butterfly Map → + Track ETRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ETRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ETRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ETRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ETRA)

Health Care Rank #458 of 1016 ⚔️ ENTX vs ETRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ETRA vs. ENTX, VALN, SRZN, RGNX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Electra Therapeutics Inc. (ETRA) ranks #458 by composite RQD confidence (43/100, grade D-) and #434 by equity capitalization ($542.3M). Within this direct 5-issuer industry benchmark cohort, ETRA leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with ETRA at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ETRA ACTIVE Electra Therapeutics Inc.	D-	43/100	—	—	—	-6.25%	$542.3M	Benchmark Subject
ENTX Entera Bio Ltd.	D-	40/100	—	0.0%	-33.6%	+2.56%	$542.6M	/entx-vs-etra →
VALN Valneva SE	D	48/100	—	—	—	-4.55%	$541.8M	/valn-vs-etra →
SRZN Surrozen Inc.	D-	38/100	—	—	-35.0%	-1.43%	$524.4M	/srzn-vs-etra →
RGNX REGENXBIO Inc.	E	27/100	—	—	-35.0%	-2.83%	$489.2M	/rgnx-vs-etra →

2. ETRA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Electra Therapeutics Inc. (ETRA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $542.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ETRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ETRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ETRA compare to ENTX and VALN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ETRA?

Where is ETRA trading relative to its 50-day, 200-day, and 52-week technical levels?

ETRA last traded at $8.10 (-6.25% on volume of 150,600 shares), positioning the stock -18.35% below its 50-day simple moving average ($9.92) and -11.38% below its 200-day simple moving average ($9.14). Across its 52-week range of $7.06 to $15.50, ETRA sits at the 12.3% percentile with a 14-day RSI of 24.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($7.09 to $9.11).

ETRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Electra Therapeutics Inc. (ETRA)?

In Trailing 12 Months, ETRA converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $15.2M in free cash flow (0.4% FCF margin).

Direct Sub-Reports: ETRA RQD Cockpit ETRA 12M Forecast ETRA Earnings & Move ETRA Dividends & DRIP ETRA Insiders & 13F ETRA Whale Options ETRA Profit Sankey ETRA News & Why

ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ETRA — Electra Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:15:41Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ETRA scores 43 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows:

Fundamental Cash Engine: 12 / 20. The pillar notes ROIC of 0% and FCF yield of 0%. For a prospective investor, this means the rating reflects no measurable return on invested capital and no free cash flow yield at the time of scoring.
Whale 13F Flow: 3 / 20. This pillar covers institutional accumulation and options positioning. It is the weakest pillar relative to its maximum, indicating little supportive institutional flow in the source data.
Insider Conviction: 9 / 20. This pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score is below midpoint, offering limited evidence of insider-driven conviction.
Macro Regime Fit: 6 / 20. The pillar reports Beta of 1.0 and sector sensitivity. Its low score suggests the stock's macro positioning is not favorable under the current regime as scored.
Forensic Balance Sheet: 13 / 20. The pillar cites Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5. This is the strongest pillar relative to its maximum, though it still falls short of a favorable reading.

Taken together, a prospective investor should view the rating as signaling weakness across cash generation, institutional flow, insider conviction, and macro fit, with balance sheet metrics providing the relative support. The market data also shows a -6.25% change on the day, and the share price of 8.1 sits near the bottom of its 52-week range of $7.95 - $15.5. Upside drivers would need to come from improved cash generation or a shift in flow, neither of which the source data demonstrates. Valuation cannot be assessed on earnings multiples, since P/E and EV/EBITDA are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the headlines include a net income item from TradingView, a TD Cowen initiation with a Buy rating and target price of $9.32 reported by Moomoo, a Benzinga piece describing a bullish initiation, a Stock Titan overview, a MarketBeat item citing an average target price of $34.00, and a TradingView estimates item. The feed does not provide the underlying net income figure or the estimate details. Two items are tagged as catalysts and the remainder as market wire.

Per the Butterfly Supply-Chain Graph, the proprietary signal is a LIQUIDITY_TAILWIND flagged BEARISH with severity score 94. The Macro Tailwind Score is 18/100. The signal cites a True Net Liquidity Index of $5,745.73B, a 4-week rate of change of -0.64%, a High-Yield OAS of +2 bps, and a rolling 5-year regression beta of 6.00x to Net Liquidity with r = +0.32. These are the risk watch items: the signal states the stock is in a liquidity-sensitive position under current plumbing conditions.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE and no butterfly links are provided. Upstream and downstream dependencies are not available in source data. Sector correlations beyond the liquidity signal are not available in source data. The investor should watch the sensitivity of ETRA to net liquidity conditions, since the signal assigns a high beta to that factor, and note that a 6.00x elasticity implies amplified exposure to changes in that backdrop. Second-order bottlenecks cannot be identified from the supplied data.

Analyst View & Smart Money Ownership

Analyst data is not available in source data. Holder data, including SEC Form 4 insider, 13F institutional, and Congressional trades, is not available in source data. The news feed references a TD Cowen Buy rating with a $9.32 target and a MarketBeat average target of $34.00; these appear only as headlines and are not verified against an analyst section.

Open Questions

What are the reported revenue, operating income, net income, and cash flow figures for recent periods, given the financials section is empty?
What products or therapies does the company develop, and what is its revenue model?
Does the $34.00 average target price cited in the news feed reconcile with the $9.32 TD Cowen target and the 8.1 current price?
What are the holdings and recent trading activity of institutional, insider, and Congressional holders?
What is the company's cash runway and debt maturity profile, given that the balance sheet metrics are summary figures only?

ETRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Electra Therapeutics Inc. (ETRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ETRA Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 9h ago

Net income of Electra Therapeutics, Inc. – NASDAQ:ETRA

TradingView report covering Electra Therapeutics Inc. (ETRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 12h ago

TD Cowen Initiates ELECTRA THERAPEUTICS INC(ETRA.US) With Buy Rating, Announces Target Price $9.32

Moomoo report covering Electra Therapeutics Inc. (ETRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Benzinga • 15h ago

This Electra Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Benzinga report covering Electra Therapeutics Inc. (ETRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

Electra Therapeutics (ETRA) Stock Price, News & Analysis

Stock Titan report covering Electra Therapeutics Inc. (ETRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 21h ago

Electra Therapeutics, Inc. (NASDAQ:ETRA) Stock Has Average Target Price of $34.00 According to Brokerages

MarketBeat report covering Electra Therapeutics Inc. (ETRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Electra Therapeutics, Inc. Estimates – NASDAQ:ETRA

TradingView report covering Electra Therapeutics Inc. (ETRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Electra Therapeutics Ord Shs (ETRA) Balance Sheet

TradingKey report covering Electra Therapeutics Inc. (ETRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Two funds hold 6.35 million Electra Therapeutics (ETRA) shares, attributed to one investor.

Stock Titan report covering Electra Therapeutics Inc. (ETRA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ETRA Bull vs. Bear Conversation Board — What's Your Call at $8.10?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ETRA 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $7.13 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ETRA (D- • RQD 43/100) a Buy at $8.10?

Welcome to the ETRA (Electra Therapeutics Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $6.40 (-21.0%)

Spot @ $8.10

Pump the brakes on ETRA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ETRA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Electra Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $9.23 (+14.0%)

Spot @ $8.10

ETRA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ETRA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $8.10 (52-wk range $7.95 - $15.50), any beat on forward guidance forces shorts and underweight funds to chase.